Feds hope to cut sepsis deaths by hitching Medicare payments to treatment stats. https://www.fiercehealthcare.com/providers/feds-hope-cut-sepsis-deaths-hitching-medicare-payments-treatment-stats The rule emphasizes the following measures: Quick Blood Tests: Hospitals must perform blood tests promptly to identify markers indicating sepsis.Timely Antibiotics: Antibiotics must be administered within three hours of identifying a possible sepsis case.Other Measures: The Severe Sepsis/Septic Shock Early Management Bundle also includes additional tests and intravenous fluids to maintain safe blood pressure levels.

Published: January 29, 2024 https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00009-9/fulltext

By GetNews Published September 19, 2022 DelveInsight’s “Septic Shock Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Septic Shock, historical and forecasted epidemiology as well as the Septic Shock market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Septic Shock market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Septic Shock pipeline products will significantly revolutionize the Septic Shock market dynamics. Septic Shock Overview According to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis3), septic shock is defined by persisting hypotension that requires vasopressors to maintain amean arterial pressure of 65 mm Hg or higher and a serum lactate level greater than 2 mm ol/L(18 mg/dL) despite adequate volume resuscitation. The symptoms of septic shock include hypotension, confusion or disorientation, diarrhea, nausea and vomiting, cold, clammy, and pale skin. Some of the key facts of the Septic Shock Market Report: The Septic Shock market size is anticipated to grow with a significant CAGR during the study period (2019-2032) Sepsis-2 septic shock accounted for three-quarters of the severe sepsis population, and the extrapolated population incidence increased from 69–79 per 100,000 person-years Key Septic Shock Companies: Adrenomed AG, Vivacelle Bio, Inotrem, and others Key Septic Shock Therapies: Adrecizumab, VBI-S, Nangibotide, and others The Septic shock epidemiology based on gender analyzed that the percentage of females who stayed in ICU due to septic shock was 36.7% Get a Free sample for the Septic Shock Market Report Key benefits of the Septic Shock Market report: Septic Shock market report covers a descriptive overview and comprehensive insight of the Septic Shock Epidemiology and Septic Shock market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) The Septic Shock market report provides insights on the current and emerging therapies. Septic Shock market report provides a global historical and forecasted market covering drug outreach in 7MM. The Septic Shock market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Septic Shock market. Discover more about therapies set to grab major Septic Shock market share @ Septic Shock market forecast Septic Shock Epidemiology Segmentation: The Septic Shock market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalence of Septic Shock Prevalent Cases of Septic Shock by severity Gender-specific Prevalence of Septic Shock Diagnosed Cases of Episodic and Chronic Septic Shock Septic Shock Market The dynamics of the Septic Shock market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Adrecizumab, VBI-S, Nangibotide, and others during the forecasted period 2019-2032. Download the report to understand which factors are driving Septic Shock epidemiology trends @ Septic Shock Epidemiological Insights Septic Shock Therapies and Key Companies Adrecizumab: Adrenomed AG VBI-S: Vivacelle Bio Nangibotide: Inotrem Scope of the Septic Shock Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Septic Shock Companies: Adrenomed AG, Vivacelle Bio, Inotrem, and others Key Septic Shock Therapies: Adrecizumab, VBI-S, Nangibotide, and others Septic Shock Therapeutic Assessment: Septic Shock current marketed and Septic Shock emerging therapies Septic Shock Market Dynamics:  Septic Shock market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL’s views, Analyst’s views, Septic Shock  Market Access and Reimbursement Table of Contents 1. Septic Shock Market Report Introduction 2. Executive Summary for Septic Shock 3. SWOT analysis of Septic Shock 4. Septic Shock Patient Share (%) Overview at a Glance 5. Septic Shock Market Overview at a Glance 6. Septic Shock Disease Background and Overview 7. Septic Shock Epidemiology and Patient Population 8. Country-Specific Patient Population of Septic Shock 9. Septic Shock Current Treatment and Medical Practices 10. Septic Shock Unmet Needs 11. Septic Shock Emerging Therapies 12. Septic Shock Market Outlook 13. Country-Wise Septic Shock Market Analysis (2019–2032) 14. Septic Shock Market Access and Reimbursement of Therapies 15. Septic Shock Market drivers 16. Septic Shock Market barriers 17.  Septic Shock Appendix 18. Septic Shock Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight To know more about Septic Shock treatment, visit @ Septic Shock Medications Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/

Published May 9, 2022 New Jersey, United States-Sepsis and Shock Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028 The report on the worldwide sepsis and shock treatment market concentrates on the past as well as flow development patterns and chances to acquire important experiences of these pointers for the market during the figure time frame from 2021 to 2028. The report gives the general income of the worldwide sepsis and shock treatment market for the period 2021-2028, thinking about 2020 as the base year and 2028 as the gauge year. The report additionally gives the build yearly development rate (CAGR) for the worldwide sepsis and shock treatment market for the gauge time frame. The report has been arranged after broad exploration. The essential examination included a greater part of exploration endeavors, wherein investigators did interviews with industry pioneers and assessment producers. The auxiliary examination included alluding to vital participants’ item writing, yearly reports, public statements, and important archives to comprehend the worldwide sepsis and shock treatment market. Receive the Sample Report of Sepsis And Septic Shock Treatment Market Insights 2022 to 2028 @ https://www.infinitybusinessinsights.com/request_sample.php?id=658521 The report involves an intricate chief rundown, alongside a preview of the development conduct of different sections and sub-fragments remembered for the extent of the review. Furthermore, the report reveals insight into the changing serious elements in the worldwide sepsis treatment market. These files act as important instruments for existing business sector players as well concerning elements keen on partaking in the worldwide sepsis and shock treatment market. The following segment of the worldwide sepsis and shock treatment market report features the USPs, which incorporate mechanical progressions, key industry occasions (consolidations, acquisitions, vital associations, and so on), the top three players working in the market space, and the COVID-19 pandemic effect on the worldwide sepsis and shock treatment market. Competitive Analysis Central membersVBI-S: Vivacelle BioNangibotide (LR12): InotremAllocetra: Enlivex TherapeuticsIdarucizumab: AdrenomedDetroja/Fetch Roja (Cefiderocol): ShionogiRecomodulin (ART-123): Asahi Kasei Pharma Corp.Recombinant human soluble phosphatase: AM-Pharma Division SegmentThe development among sections assists you with examining specialty pockets of development and systems to move toward the market and decide your center application regions and the distinction in your objective business sectors. Based on stages, the sepsis treatment market is fragmented into sepsis, serious sepsis, and septic shock. Based on microbe type, the sepsis treatment market is portioned into microorganisms, parasites, and infection. Based on the component of activity, the sepsis and shock treatment market is portioned into antimicrobials, corticosteroids, vasoactive specialists, analgesics and others. Coronavirus Impact AnalysisThe Global Sepsis and shock treatment have expressed that the novel Covid might prompt sepsis by influencing the body’s safe framework reaction toward the contamination, bringing about organ harm and even demise. Such advancements are setting out income open doors for partners in the sepsis treatment market. Coronavirus pneumonia is one of the main considerations to causes of sepsis in patients, attributable to serious lung aggravation that happens because of the original contamination. Bacterial, contagious, and viral diseases have the likelihood to cause Covid pneumonia, hence prompting sepsis. It has been tracked down that patients with extreme COVID-19 from Seattle revealed serious septic shock, which set off the interest for medications to help heart and blood courses. Download the Full Index of the Sepsis And Septic Shock Treatment Market Key Questions Answered in the ReportWhat are the deals/income created by sepsis makers across all locales during the gauge time frame?What are the critical patterns in the worldwide sepsis and shock treatment market?What are the significant drivers, restrictions, valuable open doors, and dangers on the lookout?What district is set to grow at the quickest CAGR during the figure time frame?Which portion will have the most noteworthy income around the world in 2028 and which fragment will extend at the most elevated CAGR during the conjecture time frame?What was the market positioning of various organizations working in the worldwide market in 2020? Contact Us:Amit JainSales Co-OrdinatorInternational: +1 518 300 3575Email: inquiry@infinitybusinessinsights.comWebsite: https://www.infinitybusinessinsights.com

Vivacelle Bio named included in 101 top Illinois Biotechnology Companies and Startups - 2021 https://beststartup.us/101-top-illinois-biotechnology-companies-and-startups-of-2021/

February 09, 2021 09:24 AM Eastern Standard Time DUBLIN--(BUSINESS WIRE)--The "Sepsis Pipeline Insight 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Sepsis - Pipeline Insight, 2021," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis. Sepsis Emerging Drugs Chapters This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Sepsis Emerging Drugs Rezafungin: Cidara Therapeutics Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections. Rezafungin (formerly CD101) is an echinocandin drug, currently in Phase III clinical development for candidemia, invasive candidiasis and for prophylaxis of invasive fungal infections due to Candida, Aspergillus, and Pneumocystis. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and fast track designations for rezafungin. VBI-S: Vivacelle Bio VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body's fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. The therapy is currently under phase II clinical evaluation for the treatment of hypovolemia due to sepsis/septic shock. Sepsis: Therapeutic Assessment This segment of the report provides insights about the different Sepsis drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Sepsis There are approx. 40+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. Phase III include, Cidara Therapeutics. Phases Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Products have been categorized under various ROAs such as: Oral Parenteral Intravitreal Subretinal Topical Molecule Type Products have been categorized under various Molecule types such as: Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type The drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Sepsis: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs. Sepsis Report Insights Sepsis Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Sepsis Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Questions How many companies are developing Sepsis drugs? How many Sepsis drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sepsis? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sepsis therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Sepsis and their status? What are the key designations that have been granted to the emerging drugs? Key Players Cidara Therapeutics Vivacelle Bio SciClone Pharmaceuticals Asahi Kasei Pharma Sanofi Shionogi Revimmune Inotrem Enlivex Therapeutics Abionyx Key Products Rezafungin VBI-S Thymosin alpha 1 ART-123 Alirocumab Cefiderocol CYT107 Nangibotide Allocetra-OTS CER-001 For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/j7edn5 Contacts ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

NEWS PROVIDED BY Vivacelle Bio, Inc. 24 Nov, 2020, 08:00 ET FORT WAYNE, Ind., Nov. 24, 2020 /PRNewswire/ --  Vivacelle Bio, Inc. today announces the Department of Defense awarded $5.3 million (USD) dollars for the clinical trial of VBI-S, an intravenously injected fluid based upon Vivacelle Bio's phospholipid nanoparticle technology for the treatment of septic shock due to various pathogens including COVID-19, other viruses and/or bacteria. Approximately 270,000 people in the US and 10 million people worldwide die of septic shock annually. Seventy percent of COVID deaths are due to septic shock. Vivacelle's VBI-S is likely to be effective in elevating blood pressure to survivable levels and improving oxygenation at early and even late stages of septic shock when current therapy, consisting of fluids and vasopressor medications, have failed. A phase IIa trial will be performed followed by a phase IIb/III trial of VBI-S. The award was issued on behalf of the Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) a biomedical technology consortium that collaborates under a transaction agreement (OTA) with the US Army Medical Research and Development Command (USAMRDC). The award issued is entitled "Phospholipid Nanoparticles in The Treatment of Septic Shock." VBI-S is likely to be effective in septic shock due to COVID or bacteria even when current therapy has failed. Post this Harvard Medical-school graduate and trauma surgeon, Cuthbert Simpkins, M.D., Founder of Vivacelle Bio, Chief Innovation Office and inventor of the phospholipid nanoparticle technology stated, " VBI-S is a game changer. Many years ago, I received the training that enabled me to make this discovery while I served as a Naval Officer at the Naval Medical Research Institute. I have been doing research on septic shock for nearly 40 years. Finally, we have what I and others have been seeking for all of this time, a way to save lives and to reduce suffering of patients and their loved ones. I am very grateful to the Navy for providing the opportunity to move this life saving technology forward." Harven DeShield J.D., Ph.D. and CEO of Vivacelle Bio commented, "This milestone clearly establishes both the clinical importance of VBI-S and the commercial trajectory of Vivacelle Bio. We are well poised to leverage our nanotechnology to rapidly address unmet clinical needs and save lives." About Vivacelle Bio, Inc.Vivacelle Bio, Inc. is a biopharmaceutical company focused on the discovery of life-saving interventions in critical illnesses due to a broad range of causes such as injuries resulting from warfare, major motor vehicle collisions or septic shock. Vivacelle Bio has a pipeline of products based upon its transformational phospholipid nanotechnology. For more information on VBI-S or Vivacelle Bio, please contact Harven DeShield, J.D., Ph.D. at 716-830-8932 or via email, harven@vivacellebio.com.  Company website: vivacellebio.com About Medical Technology Enterprise ConsortiumMTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command.  To find out more about MTEC, visit www.mtec-sc.org. SOURCE Vivacelle Bio, Inc. Related Links https://vivacellebio.com